New tools and emerging technologies for the diagnosis of tuberculosis: Part I. Latent tuberculosis
- 1 May 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 6 (3) , 413-422
- https://doi.org/10.1586/14737159.6.3.413
Abstract
Nearly a third of the world's population is estimated to be infected with Mycobacterium tuberculosis. This enormous pool of latently infected individuals poses a major hurdle for global tuberculosis (TB) control. Currently, diagnosis of latent TB infection (LTBI) relies on the tuberculin skin test (TST), a century-old test with known limitations. In this review, the first of a two-part series on new tools for TB diagnosis, recent advances in the diagnosis of LTBI are described. The biggest advance in recent years has been the development of in vitro T-cell-based interferon-gamma release assays (IGRAs) that use antigens more specific to M. tuberculosis than the purified protein derivative used in the TST. Available research evidence on IGRAs suggests they have higher specificity than TST, better correlation with surrogate markers of exposure to M. tuberculosis in low-incidence settings, and less cross-reactivity due to BCG vaccination than the TST. IGRAs also appear to be at least as sensitive as the purified protein derivative-based TST for active TB. In the absence of a gold standard for LTBI, sensitivity and specificity for LTBI are not well defined. Besides high specificity, other potential advantages of IGRAs include logistical convenience, avoidance of poorly reproducible measurements, such as skin induration, need for fewer patient visits and the ability to perform serial testing without inducing the boosting phenomenon. Overall, due to its high specificity, IGRAs may be useful in low-endemic, high-income settings where cross-reactivity due to BCG might adversely impact the utility of TST. However, despite the growing evidence supporting the use of IGRAs, several unresolved and unexplained issues remain. The review concludes by highlighting areas where evidence is lacking, and provides an agenda for future research. Active TB and drug resistance are discussed in Part II; 423-432 of this issue.Keywords
This publication has 37 references indexed in Scilit:
- Advances in the Diagnosis and Treatment of TuberculosisProceedings of the American Thoracic Society, 2006
- Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the fieldEuropean Respiratory Journal, 2005
- The Diagnosis of TuberculosisClinics in Chest Medicine, 2005
- Utility of the antigen-specific interferon-?? assay for the management of tuberculosisCurrent Opinion in Pulmonary Medicine, 2005
- Alternatives to the tuberculin skin test: Interferon-γ assays in the diagnosis of Mycobacterium Tuberculosis infectionIndian Journal of Medical Microbiology, 2005
- Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic reviewThe Lancet Infectious Diseases, 2004
- Avances recientes en métodos moleculares para el diagnóstico precoz y tuberculosis resistente al tratamientoBiomédica, 2004
- The Growing Burden of TuberculosisArchives of internal medicine (1960), 2003
- What Does Tuberculin Reactivity after Bacille Calmette-Guérin Vaccination Tell Us?Clinical Infectious Diseases, 2000
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000